
WHO grants EUL to CanSinoBIO’s Covid-19 vaccine
The decision is based on the totality of scientific data, including findings from a Phase III trial of Convidecia.
The decision is based on the totality of scientific data, including findings from a Phase III trial of Convidecia.
ASAP consortium will leverage the end-to-end AI-first approach of PostEra to expedite the drug discovery process.
Olverembatinib showed increased Omicron-NTD-mediated cytokine release suppression compared with ponatinib and baricitinib.
The expanded EUA for use of booster dose in children is based on the findings from a Phase II/III clinical…
The data was inadequate to conclude that the drug was effective in preventing disease progression, FDA noted.
The EC can terminate the agreement if the vaccine does not obtain marketing authorisation from EMA by the end of…
The vaccine doses planned to be supplied between June and August will now be delivered from September to Q4 of…
The grant will support two trials of ebselen in 120 adult subjects with moderate or severe Covid-19.